Prozac Generic (Fluoxetine)

Medically reviewed by Dr. Sarah Mitchell, RPh, Clinical Pharmacist — Updated April 2026

What Is Fluoxetine (Prozac Generic)? — Complete Mechanism of Action

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) — it works by selectively blocking the serotonin transporter (SERT), the membrane protein responsible for removing serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft and returning it to the presynaptic neuron for reuse or degradation. By inhibiting SERT, fluoxetine increases the concentration of serotonin available to bind postsynaptic 5-HT receptors — normalising serotonergic neurotransmission in the limbic system, prefrontal cortex, and other brain circuits implicated in mood, anxiety, and cognitive regulation.

The neurobiology of depression — why serotonin matters: Major depressive disorder is associated with hypoactivity of serotonergic projections from the raphe nuclei to the limbic system (amygdala, hippocampus) and prefrontal cortex — regions governing emotional processing, memory consolidation, and executive function. Reduced serotonergic tone in these circuits produces the characteristic symptoms of depression: persistent low mood, anhedonia (inability to feel pleasure), negative cognitive bias, sleep and appetite dysregulation, and impaired concentration. Fluoxetine's SERT inhibition gradually restores serotonergic tone in these circuits — producing clinical improvement in mood, anxiety, and cognition over 2 to 6 weeks of consistent daily dosing.

Fluoxetine's uniquely long half-life — the key pharmacokinetic advantage: Fluoxetine has the longest half-life of any commonly prescribed SSRI — a property with important clinical consequences that distinguish it from other antidepressants:

• Parent compound half-life: 1 to 4 days (approximately 24–72 hours)
• Active metabolite norfluoxetine half-life: 4 to 16 days — norfluoxetine is a potent SERT inhibitor in its own right, maintaining therapeutic drug levels for weeks after the last dose
• Effective tissue half-life: approximately 5 to 6 days on average

Clinical implications of fluoxetine's long half-life:

• Minimal discontinuation syndrome: When fluoxetine is stopped — even abruptly — the long half-life of norfluoxetine creates a gradual, self-tapering effect over several weeks. This means fluoxetine has the lowest risk of antidepressant discontinuation syndrome of all SSRIs. Patients who stop escitalopram, sertraline, or paroxetine abruptly frequently experience discontinuation symptoms (brain zaps, flu-like symptoms, dizziness, irritability, rebound anxiety) — this is rarely clinically significant with fluoxetine. This is a key advantage for Canadian patients who miss doses or need to stop medication quickly
• Missed doses are forgiving: Missing one or even two doses of fluoxetine produces minimal or no discontinuation symptoms — in contrast to shorter half-life SSRIs where even a single missed dose can trigger discontinuation effects
• Once-daily dosing with stable plasma levels: The long half-life produces very stable plasma concentrations with once-daily dosing — there are no significant peak-and-trough fluctuations that might contribute to mood instability
• Drug interactions persist after stopping: Fluoxetine's strong CYP2D6 inhibition and long half-life means interactions with other CYP2D6-metabolised drugs can persist for 4 to 5 weeks after fluoxetine is discontinued. This is clinically important when switching to certain other antidepressants or starting medications metabolised by CYP2D6 (including atomoxetine/Strattera)

Health Canada-Approved Indications for Fluoxetine in Canada

1. Major Depressive Disorder (MDD) — primary indication: Fluoxetine is a first-line antidepressant for MDD per CANMAT 2023 guidelines. It is effective across all severity levels — mild, moderate, and severe depression. According to Statistics Canada, depression affects approximately 5.4% of the Canadian population aged 15 and older in any given year — roughly 1.6 million Canadians. Fluoxetine's particular advantage in depressed patients with comorbid lethargy, hypersomnia, excessive fatigue, and psychomotor retardation (the so-called "atypical" features or melancholic features with prominent energy impairment) relates to its mild activating profile — compared to sedating antidepressants, fluoxetine tends to increase energy and motivation rather than causing sedation.

2. Obsessive-Compulsive Disorder (OCD): SSRIs at higher doses are the gold-standard pharmacotherapy for OCD per CANMAT and international guidelines. Fluoxetine 40–80mg daily — doses substantially higher than used for depression — is effective for OCD when combined with cognitive-behavioural therapy using Exposure and Response Prevention (ERP). OCD affects approximately 1–2% of Canadians. The higher doses required for OCD (40–80mg vs 20–40mg for depression) reflect the different neurobiological basis of OCD response to serotonergic agents — Canadian physicians will typically start at 20mg and titrate more aggressively for OCD than for depression.

3. Panic Disorder: Fluoxetine reduces panic attack frequency, severity, and anticipatory anxiety in panic disorder. A key prescribing consideration: start at a very low dose (5–10mg — achieved by halving a 10mg capsule or using liquid formulation if available) due to fluoxetine's initial anxiogenic effect that can temporarily increase anxiety in the first 1–2 weeks before the therapeutic anxiolytic effect develops. This "start low" principle is particularly important for Canadian patients with panic disorder.

4. Bulimia Nervosa: Fluoxetine 60mg daily is the only antidepressant with a Health Canada and FDA indication specifically for bulimia nervosa — reducing binge-eating frequency, purging behaviour, and associated psychological distress. The 60mg dose used for bulimia is higher than the 20–40mg used for depression. For Canadian patients seeking treatment for bulimia, fluoxetine combined with cognitive-behavioural therapy for eating disorders produces the best outcomes per current evidence.

5. Premenstrual Dysphoric Disorder (PMDD): PMDD affects approximately 3–8% of Canadian women of reproductive age — causing severe mood symptoms, irritability, anxiety, and physical symptoms in the 1–2 weeks before menstruation. Fluoxetine is effective for PMDD in two dosing regimens: continuous 20mg daily throughout the month, or luteal phase dosing (20mg starting 14 days before menstruation — taken only in the second half of the menstrual cycle). Both approaches are evidence-based.

6. Off-label uses with substantial evidence: Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Post-Traumatic Stress Disorder (PTSD), binge eating disorder, depressive episodes in bipolar disorder (with mood stabiliser), body dysmorphic disorder.

Fluoxetine vs Other SSRIs — The Canadian Comparison

Canadian physicians and psychiatrists choose between several SSRIs for first-line depression and anxiety treatment. The most common comparisons Canadian patients search for:

Canadian Dosing Protocol

Depression and Anxiety (standard starting dose):

• Starting dose: 20mg once daily in the morning (morning dosing preferred to minimise insomnia — fluoxetine's activating profile can disrupt sleep if taken at night)
• Assessment at 4 weeks: If response is inadequate and drug is well-tolerated, increase to 40mg/day
• Maximum dose for depression/anxiety: 80mg/day (rarely needed; most patients respond at 20–40mg)
• Usual effective dose range: 20–40mg/day

OCD:

• Starting dose: 20mg/day; increase gradually to 40–60mg/day
• Target dose: 40–80mg/day — OCD typically requires higher doses than depression
• Allow 8–12 weeks at optimal dose before assessing OCD response (longer than for depression)

Panic Disorder:

• Start extremely low: 5–10mg/day (cut a 10mg capsule if needed, or use liquid formulation) for the first 1–2 weeks to avoid initial anxiogenic effect
• Gradually increase to 20–40mg/day as tolerated

Bulimia Nervosa:

• Target dose: 60mg/day — higher than for depression
• Start at 20mg and titrate up over 1–2 weeks

PMDD:

• Continuous: 20mg/day throughout the month
• Luteal phase (intermittent): 20mg/day for 14 days before expected menstruation — stop at onset of menstruation

Critical counselling point — delayed onset: Fluoxetine does not produce antidepressant effects immediately. Most Canadian patients require 2 to 6 weeks of consistent daily dosing before experiencing meaningful improvement in mood. Full antidepressant response may take 8 to 12 weeks. This delayed onset is the most important information for patients starting fluoxetine — many Canadians stop their medication prematurely (within 2 to 4 weeks) because they don't yet feel better. Continue taking fluoxetine as prescribed through the initial period and discuss any concerns with your physician before making changes.

Side Effects — Complete Canadian Guide

Very common — affecting >10% of patients, especially initially:

• Nausea: Most common initial side effect — typically worst in the first 1 to 2 weeks and resolves as the body acclimatises. Take fluoxetine with food to reduce nausea. If severe, consider splitting the dose or taking it with a larger meal
• Headache: Common in the first 2 to 4 weeks; usually resolves with continued use. Paracetamol/acetaminophen is appropriate for headache management during this adjustment period
• Insomnia or sleep disturbance: Fluoxetine's activating effect can disrupt sleep if taken in the evening — always take in the morning. Initial insomnia usually improves after 2 to 4 weeks as the body adjusts
• Reduced appetite: Common initially — usually transient. Significant sustained appetite reduction is uncommon at standard doses
• Agitation and restlessness (akathisia): Some patients, particularly with anxiety disorders, notice increased agitation or restlessness in the first 1 to 3 weeks — the "initial anxiety worsening" phenomenon. This is temporary and resolves; if severe, contact your physician who may temporarily reduce the dose

Common — affecting 1–10% of patients:

• Sexual dysfunction — the SSRI class effect: Sexual side effects are a very common reason Canadian patients discontinue antidepressants — affecting 30–70% of SSRI users to varying degrees. Fluoxetine causes: decreased libido (reduced sexual desire), delayed orgasm or anorgasmia (inability to orgasm), and in men, delayed or absent ejaculation and erectile dysfunction. These effects are dose-dependent — lower doses cause less sexual dysfunction. Options for managing SSRI-induced sexual dysfunction in Canadian practice include: dose reduction, switching to a different antidepressant (bupropion/Wellbutrin has the lowest sexual side effect risk of any antidepressant), "drug holidays" (skipping doses before anticipated sexual activity — less practical with fluoxetine's long half-life than with shorter half-life SSRIs), or adding adjunctive medications (sildenafil for men; buspirone for both sexes)
• Diarrhoea or GI upset — usually transient in the first few weeks
• Dizziness — usually mild; avoid activities requiring alertness until the effect is assessed
• Dry mouth — stay hydrated; sugar-free gum can help
• Sweating — increased sweating including night sweats; dose timing and dose adjustment can help
• Tremor — fine hand tremor; usually mild; dose reduction often helps

Serious — requiring immediate medical attention:

• Serotonin syndrome: A rare but potentially life-threatening condition caused by excessive serotonergic activity — most commonly when SSRIs are combined with other serotonergic medications. Symptoms: agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle twitching or rigidity, hyperthermia, diarrhoea. Medical emergency — stop fluoxetine immediately and seek emergency care. Highest risk when combining fluoxetine with: MAO inhibitors (absolute contraindication), tramadol, linezolid, methylene blue, triptans, St. John's Wort, other serotonergic antidepressants
• Hyponatraemia (low blood sodium): SSRI-induced hyponatraemia occurs particularly in elderly patients and those on diuretics — symptoms include headache, confusion, weakness, and in severe cases seizures. Report any unusual neurological symptoms to a physician promptly
• Bleeding risk: SSRIs reduce platelet aggregation — increasing risk of bruising and bleeding, particularly GI bleeding. Higher risk when combined with NSAIDs (ibuprofen, naproxen), aspirin, or anticoagulants (warfarin, apixaban, rivaroxaban). Canadian patients taking these combinations should be monitored and may benefit from a proton pump inhibitor
• Mania/hypomania activation: In patients with undiagnosed bipolar disorder, SSRIs can trigger manic or hypomanic episodes. Report any sudden elevation in mood, decreased need for sleep, racing thoughts, or impulsive behaviour to a physician immediately

Health Canada Black Box Warning — Suicidality in Young Patients

Health Canada requires fluoxetine (and all antidepressants) to carry a prominent warning regarding increased risk of suicidal thoughts and behaviours in children, adolescents, and young adults under 25 years of age — particularly during the first few weeks of treatment and following dose increases.

This warning does not mean antidepressants should be avoided in young people — untreated depression carries a substantially higher risk of suicide than antidepressant-treated depression. The warning means:

• Close monitoring by a healthcare provider is essential in the first 4 weeks — weekly contact (in person or by telephone) is recommended by CANMAT for the first month in patients aged under 25
• Patients and families should be counselled to report any worsening suicidal thoughts, self-harm ideation, agitation, or unusual behavioural changes to the prescribing physician immediately — without waiting for the next scheduled appointment
• Emergency action: If suicidal thoughts emerge or worsen — call 9-8-8 (Canada Suicide Crisis Helpline), call 911, or go to the nearest emergency department immediately

Critical Drug Interactions

• MAO inhibitors (MAOIs — phenelzine, tranylcypromine, selegiline, moclobemide): Absolute contraindication — combining fluoxetine with an MAOI or starting an MAOI too soon after stopping fluoxetine causes potentially fatal serotonin syndrome. Wait a minimum of 14 days after stopping an MAOI before starting fluoxetine. Wait a minimum of 5 weeks (35 days — approximately 5 half-lives of norfluoxetine) after stopping fluoxetine before starting an MAOI. This 5-week washout is much longer than for other SSRIs (typically 14 days) due to fluoxetine's uniquely long half-life
• Atomoxetine (Strattera) — significant interaction: Fluoxetine is a potent CYP2D6 inhibitor — it dramatically slows atomoxetine metabolism, increasing atomoxetine plasma levels 5 to 10 fold. Canadian patients prescribed both fluoxetine and atomoxetine require very careful dose management with close physician supervision — atomoxetine should be started at the lowest dose and titrated extremely slowly
• Tricyclic antidepressants (amitriptyline, nortriptyline, imipramine): Fluoxetine inhibits CYP2D6-mediated metabolism of tricyclics, substantially increasing tricyclic plasma levels and toxicity risk. Avoid combination or use with very careful plasma level monitoring
• Antipsychotics metabolised by CYP2D6 (haloperidol, risperidone, aripiprazole, thioridazine): Fluoxetine increases plasma levels of these agents — dose adjustment may be required
• Warfarin and anticoagulants: Fluoxetine can increase warfarin anticoagulant effect through CYP2C9 inhibition — INR monitoring is important when starting or stopping fluoxetine in patients on warfarin
• NSAIDs and aspirin: Additive antiplatelet/bleeding effect — increased GI bleeding risk. Use with caution; consider proton pump inhibitor co-prescription
• Benzodiazepines (diazepam, alprazolam): Fluoxetine mildly inhibits CYP3A4 — may increase benzodiazepine levels modestly; monitor for increased sedation
• Tamoxifen: Fluoxetine's strong CYP2D6 inhibition reduces conversion of tamoxifen to its active metabolite endoxifen — potentially reducing tamoxifen's anti-cancer efficacy. Canadian oncology guidelines advise avoiding fluoxetine in breast cancer patients taking tamoxifen; consider sertraline or venlafaxine (lower CYP2D6 inhibition) instead
• St. John's Wort (Hypericum perforatum): Serotonin syndrome risk when combined with fluoxetine — a significant concern given widespread OTC availability in Canadian pharmacies. Avoid combination

Depression in Canada — Context and Resources

Major depressive disorder is one of the most prevalent health conditions in Canada. According to Statistics Canada and the Canadian Mental Health Association:

• Approximately 5.4% of Canadians aged 15+ met criteria for a major depressive episode in the past year — over 1.6 million people
• Depression is the leading cause of disability in Canada, accounting for more lost workdays than most other health conditions
• Canadian women are approximately twice as likely as men to experience depression — with postpartum depression affecting 10–15% of new mothers in Canada; perinatal (pregnancy and postpartum) depression is now Canada's most common complication of childbirth
• Over 12% of Canadians aged 12 and older reported using antidepressants in the most recent Canadian Community Health Survey — one of the highest per-capita rates in the developed world
• Despite high prescription rates, treatment gaps remain substantial — many Canadians with depression do not receive evidence-based treatment

Canadian mental health resources:

• 9-8-8 Suicide Crisis Helpline: Call or text 9-8-8 — 24/7, bilingual (English and French)
• CMHA (Canadian Mental Health Association): cmha.ca — province-specific crisis lines and community resources
• BounceBack (CMHA): Free guided self-help CBT program for mild-to-moderate depression — GP referral required in most provinces
• CAMH (Centre for Addiction and Mental Health): camh.ca — evidence-based mental health information and treatment resources
• Postpartum Support International Canada: 1-800-944-4773 — support for postpartum depression and anxiety

Delivery to All Canadian Provinces and Territories

drugs-canada.com ships Prozac Generic discreetly to all Canadian provinces and territories. Standard delivery: 4–9 business days.

Ontario (Toronto, Ottawa, Hamilton, London, Brampton, Mississauga, Kitchener-Waterloo) — Quebec (Montreal, Quebec City, Laval, Gatineau, Sherbrooke) — British Columbia (Vancouver, Surrey, Burnaby, Victoria, Kelowna, Abbotsford) — Alberta (Calgary, Edmonton, Red Deer, Lethbridge) — Manitoba (Winnipeg, Brandon) — Saskatchewan (Saskatoon, Regina) — Nova Scotia (Halifax, Sydney) — New Brunswick (Moncton, Saint John, Fredericton) — Newfoundland and Labrador (St. John's, Corner Brook) — Prince Edward Island (Charlottetown) — Northwest Territories (Yellowknife) — Yukon (Whitehorse) — Nunavut (Iqaluit).

All orders are dispatched in plain, unmarked packaging with no reference to the contents or sender. Every order includes a tracking number.

Frequently Asked Questions — Prozac Generic (Fluoxetine) in Canada

How long does fluoxetine take to work for depression in Canada? Fluoxetine typically requires 2 to 6 weeks of consistent daily dosing before meaningful improvement in depressive symptoms is noticed — with full antidepressant response often taking 8 to 12 weeks. This delayed onset is the most important counselling point for Canadian patients starting fluoxetine. The medication is working during this period even if the effect is not yet subjectively felt — neuroadaptive changes in serotonin receptor sensitivity and downstream signalling take weeks to develop. Many Canadians stop antidepressants prematurely (within 2 to 3 weeks) because they don't feel better yet. Continuing as prescribed through the initial period is essential. If there is no meaningful response after 6 to 8 weeks at a therapeutic dose, discuss dose adjustment or switching with your physician.

What are the sexual side effects of fluoxetine and how common are they? Sexual dysfunction is the most common reason Canadian patients discontinue antidepressants — affecting an estimated 30–70% of SSRI users to varying degrees. Fluoxetine causes decreased libido, delayed orgasm or inability to orgasm (anorgasmia), and in men, delayed ejaculation and erectile dysfunction. These effects are dose-dependent — lower doses cause less sexual dysfunction. If sexual side effects are significantly affecting quality of life, discuss options with your physician: dose reduction, switching antidepressant class (bupropion/Wellbutrin has the lowest sexual side effect profile of any antidepressant), or adjunctive medications.

Is fluoxetine safe during pregnancy or breastfeeding? This is one of the most common questions from Canadian women of reproductive age on antidepressants. Fluoxetine is classified Pregnancy Category C in Canada — it crosses the placenta and enters breast milk. It is not without fetal risk (neonatal adaptation syndrome has been reported in newborns exposed in the third trimester), but untreated depression in pregnancy also carries significant risks to mother and baby. The decision to continue, switch, or taper antidepressants during pregnancy or breastfeeding is highly individual and must be made in consultation with your Canadian physician or obstetrician — ideally with input from a perinatal psychiatrist. Fluoxetine is one of the better-studied antidepressants in pregnancy, with a large safety dataset. Do not stop fluoxetine abruptly during pregnancy without medical guidance.

Why does fluoxetine cause fewer withdrawal symptoms than other antidepressants? Fluoxetine's uniquely long half-life — 1 to 4 days for the parent compound and 4 to 16 days for its active metabolite norfluoxetine — means that when fluoxetine is stopped, its plasma level declines very slowly over several weeks. This gradual, natural taper prevents the rapid serotonin withdrawal that produces discontinuation syndrome with shorter half-life SSRIs (sertraline, escitalopram, paroxetine). Paroxetine, with a half-life of only 21 hours, has the most severe discontinuation syndrome of any SSRI — symptoms can begin within 24 hours of the last dose. With fluoxetine, discontinuation symptoms are rarely clinically significant even with abrupt cessation.

Can I drink alcohol while taking fluoxetine? Alcohol should be avoided or significantly limited during fluoxetine treatment for several reasons: (1) alcohol is a depressant that directly counteracts antidepressant treatment and worsens depression; (2) both fluoxetine and alcohol affect the CNS — combination can increase sedation, dizziness, and impaired coordination; (3) alcohol can worsen anxiety and sleep disturbance — common symptoms in depressed patients; (4) heavy alcohol use is associated with poor antidepressant response. Occasional very modest alcohol consumption is generally not dangerous with fluoxetine, but regular or heavy use is incompatible with effective depression treatment.

How long does delivery to Canada take? Standard delivery to all Canadian provinces and territories takes 4 to 9 business days. All orders arrive in plain, unmarked packaging with no reference to the contents or sender. Every order includes a tracking number.

All information on this page is for general informational purposes only and does not constitute medical advice. Fluoxetine (Prozac Generic) is a Schedule F prescription medicine in Canada — a valid prescription from a licensed Canadian healthcare provider is required. Always consult a qualified Canadian physician or psychiatrist before starting, changing, or stopping antidepressant therapy. If you are experiencing suicidal thoughts or a mental health crisis, call or text 9-8-8 (Canada Suicide Crisis Helpline, 24/7) or go to your nearest emergency department.